|
|
|
|
||
ESMO LBALBA45 - Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/show/session/273 |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1236 | Re: ESMO LBA | liuyiiv | 2 | 9/26/2018 10:50:16 PM |
1237 | Re: ESMO LBA | fairvalueforyou | 1 | 9/26/2018 10:58:02 PM |